Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

NCT05867030 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development strategy adjustment

Conditions

Follicular Lymphoma

Interventions

DRUG: lenalidomide
DRUG: rituximab
DRUG: parsaclisib

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.